The week in health tech, explained in plain English.Get the free newsletter →
September 21, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Alkermes Orexin Agonist Shows Early Promise in ADHD

By Healthcare Technology News ·

Alkermes said its experimental orexin agonist showed potential to treat people with ADHD in an early-stage study, according to STAT News. It is the first time this class of drugs has signaled promise against the condition.

Orexin agonists work on brain signaling tied to wakefulness and arousal. Until now, drugmakers have chased them mainly for sleep disorders such as narcolepsy, where boosting orexin activity helps patients stay awake. Applying the same mechanism to ADHD is a new direction, and a positive early readout suggests the pathway may influence attention and focus, not just sleep.

The practical stakes are large. ADHD treatment still leans heavily on stimulants like Adderall and Ritalin, which carry abuse potential and supply shortages. A non-stimulant option with a novel mechanism could reshape prescribing if later trials hold up. Early-stage results are preliminary, and Alkermes will need larger, controlled studies to confirm the effect and define safety before the therapy nears approval.

Sources

More in Finance

Finance

The Hidden Costs Buried in Healthcare Payment Operations

Healthcare payment costs are split across four budgets, hiding the true expense of manual and paper-based processes from finance leaders.

Why it matters: Payment operations quietly drain money that organizations cannot see because the costs are fragmented across departments.

Finance

FDA Approves First Sanfilippo Gene Therapy From Ultragenyx

The FDA approved Ultragenyx's Fayuvi as the first therapy targeting the underlying cause of Sanfilippo syndrome type A.

Why it matters: It gives children with an ultra-rare, fatal neurological disorder their first approved treatment aimed at the disease's root cause.

Finance

Definium's LSD Therapy Eases Anxiety in Second Large Trial

Definium said its LSD-based therapy reduced anxiety in a second large trial, advancing the psychedelic drug class toward regulatory approval.

Why it matters: Positive late-stage data pushes psychedelic medicine closer to its first approvals, signaling a potential new category of fast-acting mental-health treatments.